Singapore, May 28 -- Insilico Medicine, a Hong Kong-headquartered clinical-stage generative artificial intelligence (AI)-driven biotechnology company, and Human Life Foundation Models, Inc. (HLFM), a newly launched company established by US-based Human Longevity, Inc., have announced a multi-million-dollar AI co-development collaboration to build industry's first large-scale foundation models dedicated to human longevity science.

According to recent analysis by UBS, the global longevity market is currently valued at approximately $5.3 trillion and is on a trajectory to reach $8 trillion by 2030. Propelling this evolution is AI-driven drug discovery, which has emerged as a cornerstone of aging research by modeling ageing biology, predicti...